Another lncRNA ZFAS1 is shown to be upregulated by PERK/ATF4 axis after sorafenib treatment in sorafenib-resistant HCC cells, which suggests that ZFAS1 may be a therapeutic or prognostic biomarker of sorafenib treatment in HCC patients [135]. This evidence concerns the gene ATF4 and hepatocellular carcinoma.